Jeb Keiper, M.S., M.B.A., Appointed Nimbus Discovery CBO
Key hire bolsters partnering and financing efforts
CAMBRIDGE, Mass. – November 4, 2014 – Nimbus Discovery LLC, a biotechnology company discovering novel medicines against important, but previously inaccessible drug targets, today announced the appointment of Jeb Keiper as Chief Business Officer. In this role, Mr. Keiper is responsible for structuring, negotiating and executing successful strategic alliances, co-development agreements, and financial investments, as well as providing management and strategic leadership to the organization. Mr. Keiper takes over the reins as Chief Business Officer from Jonathan Montagu, who remains a key contributor for Nimbus Discovery, and who is now based out of Europe.
Mr. Keiper brings over 15 years of experience in pharmaceutical and biotech companies and was previously the Vice President of Business Development for GSK Oncology. In this role, he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including his leadership of the $16B Novartis-GSK Oncology integration. Prior to GSK, Mr. Keiper held positions in business development with multiple companies and served as a consultant at McKinsey & Company, after having started his career as a pharmaceutical chemist.
Don Nicholson, Chief Executive Officer of Nimbus Discovery, said: “It is a great pleasure to welcome Jeb to our management team at Nimbus. Jeb brings valuable corporate development skills, leadership experience, and relationships across the industry. He joins at a transformational time for Nimbus Discovery as our lead program, the first allosteric inhibitor of acetyl-CoA carboxylase (ACC), enters patients in early 2015. Jeb will be instrumental as we intensify our partnering and financing efforts to further advance our broad pipeline in oncology, immunology and metabolic disorders, and continue to build on the success of our platform.”
Mr. Keiper holds four degrees from the Massachusetts Institute of Technology (MIT); one in Chemistry, two in Chemical Engineering, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.
Nimbus Discovery Inc., a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches, and its robust pre-clinical pipeline currently includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures and Bill Gates. The company has been named by FierceBiotech as one of 2013’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. For more information please visit www.nimbustx.com.